COLA: Asthma guidelines

Session recorded on August 21, 2017.

Speaker: Michael B. Foggs, MD

Viewers can earn credit by completing the posttest questions.

Despite detailed evidence-based NAEPP Asthma Guidelines recommendations and guidance from international asthma guidelines, asthma management and control in US patients in many cases remains suboptimal and fall short of treatment targets.  Some studies have demonstrated that 40 – 60% of asthmatics in the US have uncontrolled asthma.  Therefore, this video provides a better understanding of asthma diagnosis, assessment, and treatment paradigms that may help satisfy the unmet needs to optimize asthma control and to decrease asthma morbidity and mortality.

Target Audience

Practicing Allergists / Immunologists
Fellows-in-Training

Learning Objectives

After viewing the video recording, learners should be able to…

  • Describe the asthma paradigm of current impairment & future risk.
  • Define asthma severity & asthma control & distinguish between the two.
  • Discuss mechanisms by which airway remodeling can occur.
  • Articulate potential damage to the airways caused by an asthma exacerbation.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner
Speaker, Honorarium: Thermofisher, Boehringer Ingelheim

Michael B. Foggs, MD, Speaker
Consultant/Speaker, Fees/Honorarium: AstraZeneca, Boehringer Ingelheim, Genentech, Noavartis
Consultant, Fees: Boston Scientific, Mylan, Teva

The following have no financial relationships to disclose:

Paul Dowling, MD, Planner

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
08/29/2017
Course expires: 
08/28/2019
Cost:
$35.00
Rating: 
0

Michael B. Foggs, MD
Chief of Allergy, Asthma & Immunology
Advocate Health Care
Chicago, IL

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
08/29/2017
Course expires: 
08/28/2019

Price

Cost:
$35.00
Please login or create an account to take this course.